Septerna, Inc. Common Stock (SEPN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Septerna, Inc. Common Stock stock (SEPN) is currently trading at $24.21. Septerna, Inc. Common Stock PS ratio (Price-to-Sales) is 23.63. Analyst consensus price target for SEPN is $43.86. WallStSmart rates SEPN as Sell.
- SEPN PE ratio analysis and historical PE chart
- SEPN PS ratio (Price-to-Sales) history and trend
- SEPN intrinsic value — DCF, Graham Number, EPV models
- SEPN stock price prediction 2025 2026 2027 2028 2029 2030
- SEPN fair value vs current price
- SEPN insider transactions and insider buying
- Is SEPN undervalued or overvalued?
- Septerna, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- SEPN Piotroski F-Score and Altman Z-Score
- SEPN analyst price target and Smart Rating
Septerna, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Septerna, Inc. Common Stock (SEPN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Septerna, Inc. Common Stock (SEPN) Key Strengths (2)
Revenue surging 11276.00% year-over-year
102.96% of shares held by major funds and institutions
Supporting Valuation Data
Septerna, Inc. Common Stock (SEPN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 23.6x annual revenue
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Septerna, Inc. Common Stock (SEPN) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 11276.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (23.63), Price/Book (2.84) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -12.20%, Operating Margin at -66.40%, Profit Margin at -106.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -12.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 11276.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SEPN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SEPN's Price-to-Sales ratio of 23.63x trades at a deep discount to its historical average of 1129.37x (0th percentile). The current valuation is 100% below its historical high of 7510.8x set in Dec 2024, and 0% above its historical low of 23.63x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~254.1x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Septerna, Inc. Common Stock (SEPN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Septerna, Inc. Common Stock is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 46M with 11276% growth year-over-year. The company is currently unprofitable, posting a -106.4% profit margin.
Key Findings
Revenue growing at 11276% YoY, reaching 46M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.06 indicates a conservative balance sheet with 320M in cash.
The company is unprofitable with a -106.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -15M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Septerna, Inc. Common Stock maintain 11276%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Septerna, Inc. Common Stock.
Bottom Line
Septerna, Inc. Common Stock is a high-conviction growth story with revenue accelerating at 11276% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -106.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Septerna, Inc. Common Stock(SEPN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Septerna, Inc. is an innovative biotechnology company at the forefront of developing transformative therapeutics via selective protein modulation. With a commitment to addressing unmet medical needs across diverse disease areas, Septerna leverages proprietary platforms and deep scientific acumen to advance a robust pipeline of next-generation drug candidates. The company's strategic focus on research and development, coupled with its potential for significant clinical impact, positions it as a compelling opportunity for institutional investors seeking exposure in the dynamic biopharmaceutical sector.